GlassScriptPhysician profile
Rabindra Ghimire
NPI 1629363361
$15,182.36
in general payments reported to CMS, 2019-2025
16 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $291 · 2021: $3,321 · 2022: $8,850 · 2023: $319 · 2024: $1,596 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Travel and Lodging: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.73 |
| Travel and Lodging | $1,027.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $13,723.65 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $508.73 | 2019-2025 | Yeztugo |
| Janssen Products, LP | $284.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $200.55 | 2019-2023 | Dificid, Zerbaxa, Prevymis |
| Janssen Biotech, INC. | $150.81 | 2019-2023 | Symtuza |
| Tetraphase Pharmaceuticals, INC. | $99.80 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $41.76 | 2019-2020 | |
| Theratechnologies INC. | $30.80 | 2020-2021 | |
| Allergan, INC. | $29.07 | 2020 | |
| Melinta Therapeutics, LLC | $22.99 | 2023 | Rezzayo |
| Abbvie INC. | $19.08 | 2021 | |
| Insmed, INC. | $16.27 | 2019 | |
| Amgen INC. | $14.09 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.95 | 2022 | |
| La Jolla Pharmaceutical Company | $13.76 | 2023 | Xerava |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabindra Ghimire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.